|Auflage||4. Auflage, 2015|
|Verlag||Elsevier Health Care - Major Reference Works|
Atlas of Diagnostic Oncology, 4th Edition, by Arthur T. Skarin, MD, FACP, FCCP, provides the guidance you need to diagnose a full range of neoplastic conditions with greater accuracy for better patient outcomes. An unrivaled collection of more than 2,500 images and drawings-combined with succinct, clinically focused text-equips you with essential information on pathology, diagnostic studies, staging, and clinical manifestations. New discussions on modern diagnostic PET imaging of cancer, and expanded coverage on the side effects of chemotherapy, bring you up to date on the issues impacting research and treatment. Expert Consult functionality-new to this edition-further enhances your reference power with convenient online access to the complete contents of the text, along with case studies that demonstrate effective approaches to diagnosis.
Your purchase entitles you to access the web site until the next edition is published, or until the current edition is no longer offered for sale by Elsevier, whichever occurs first. Elsevier reserves the right to offer a suitable replacement product (such as a downloadable or CD-ROM-based electronic version) should access to the web site be discontinued.
Arthur T. Skarin, MD, FACP, FCCP, earned his MD from the State University of New York at Buffalo in 1961, and received postgraduate training in internal medicine at the Millard Fillmore Teaching Hospital in Buffalo. After a fellowship in hematology and oncology at Boston City Hospital, he joined Brigham and Women's Hospital and Dana-Farber Cancer Institute (DFCI) in 1970. He served as Clinical Director of the DFCI Hematology Laboratory as well as Chairman of the Laboratory Committee from 1970 to 1998. He established the multimodality thoracic oncology clinic in 1975 and has served as Medical Director since then. During that time he also was chair of the human protection committee (IRB) for 12 years and became Associate Professor of Medicine at Harvard Medical School. He has been the Principal Investigator (PI) as well as site PI on numerous clinical research Phase I, II and III trials, both at DFCI Partners Cancer Care and the Cancer and Leukemia Group B (CALGB). He was appointed a Research Subject Advocate (RSA) in 2002 for NIH funded studies at the Brigham and Women's Hospital General Clinical Research Center (GCRC) and DFCI. Dr. Skarin is a board member of the American Journal of Oncology Review, the Journal of Cinical Oncology, Hospital Physician and also president of the Massachusetts Society of Clinical Oncologists. He has published 150 original articles, 97 abstracts, 67 chapters in books and 4 books.